Who writes the research library?
The PepMate Research Desk is the editorial identity used for PepMate’s educational research library. It is an organizational byline, not a claim that a physician personally reviewed every sentence. We do not invent an expert credential, medical reviewer, or firsthand clinical experience that we do not have.
PepMate is built by Protasys and provides medication tracking, reminders, injection-site notes, and personal logs. The app does not diagnose, prescribe, recommend peptides, calculate dosing, or sell medication. The research library exists to help readers distinguish published evidence from advertising before discussing their own care with a licensed clinician.
How sources are selected
Every peptide guide links directly to papers indexed on PubMed. We prioritize evidence in this order: systematic reviews and meta-analyses; randomized controlled trials; large prospective or observational human studies; smaller human pharmacology studies; and then animal or cell research when human evidence is absent.
For emerging peptides, the absence of human trials is itself a central finding. We do not fill that gap by treating a receptor mechanism, mouse experiment, patent, clinic testimonial, or product listing as equivalent evidence. Papers are chosen to show both the strongest positive findings and the limitations or safety signals that materially change interpretation.
How evidence is graded
| Evidence level | What it means on PepMate |
|---|---|
| Strong human evidence | Multiple controlled trials, major outcome studies, or an established indication with a mature safety record. |
| Indication-specific evidence | Good trials for a narrow disease or genetically defined population; not proof for broader wellness use. |
| Early human evidence | Small trials, pharmacology studies, or regional literature that needs independent replication. |
| Preclinical evidence | Cell and animal research that can justify further study but cannot establish a human treatment. |
| Insufficient evidence | No reliable clinical program supports the commonly marketed claim. |
Approval and regulatory language
“Peptide” is a chemical description, not a regulatory category. An FDA-approved peptide medicine, an investigational drug in a registered trial, a patient-specific compounded prescription, and an online vial labeled “research use only” are materially different. Each guide states which category applies and avoids language that turns availability into legitimacy.
Approval is tied to a product, formulation, population, and indication. A drug approved for diabetes is not automatically approved for weight management; a peptide used for a rare genetic disease is not proven for common obesity. Because regulation changes, readers should verify current labeling with the relevant regulator and clinician.
Medical scope and safety
Articles explain study designs, endpoints, mechanisms, adverse effects, and evidence gaps. They intentionally exclude doses, injection protocols, cycling, reconstitution, sourcing, and individualized advice. A PubMed citation is not a recommendation, and a page ranking in search does not make a compound appropriate for anyone.
Unapproved products add quality risks that published pharmacology may not capture: the vial may contain the wrong compound, concentration, contaminant, or microbial burden. We say this explicitly whenever online or black-market use is part of the search intent.
Updates and corrections
Every research guide displays a last-updated date and structured date metadata. We revise pages when major trial results, approvals, safety warnings, or regulatory changes alter the answer. We also run automated checks for unique titles and descriptions, valid structured data, working internal links, canonical URLs, PubMed references, and App Store calls to action.
If you find a factual error, broken citation, missing limitation, or outdated approval statement, email [email protected] with the page URL and supporting source. Material corrections are made in the article and reflected in its modified date.
Commercial independence
PepMate earns revenue from its tracking app, not from peptide sales, clinics, pharmacies, or supplement affiliate links. Research pages end with an invitation to download PepMate because the product helps users keep clinician-directed regimens organized. The CTA does not change the evidence assessment, and articles do not recommend starting a compound.